专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005004838A8 PHARMACEUTICAL FORMULATIONS FOR INTRANASAL ADMINISTRATION OF PROTEIN COMPRISING A CHITOSAN OR A DERIVATIVE THEREOF 审中-公开
标题翻译：用于包含壳聚糖或其衍生物的蛋白质的肠内给药的药物制剂
公开(公告)号：WO2005004838A8
公开(公告)日：2005-03-17
申请号：PCT/GB2004002876
申请日：2004-07-02
申请人： WEST PHARM SERV DRUG RES LTD , DYER ANN MARGARET , WATTS PETER JAMES , CHENG YU-HUI , SMITH ALAN
发明人： DYER ANN MARGARET , WATTS PETER JAMES , CHENG YU-HUI , SMITH ALAN
IPC分类号： A61K9/00 , A61K9/16 , A61K38/27 , A61K47/36 , A61P43/00
CPC分类号： A61K9/0043 , A61K9/1652 , A61K38/27 , A61K47/36 , Y10S514/951
摘要： There is provided a powder formulation for nasal delivery comprising a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.
摘要翻译：提供了一种用于鼻腔输送的粉末制剂，其包含分子量为10kDa或更高的蛋白质和壳聚糖或其衍生物或壳聚糖的盐或壳聚糖衍生物的盐。优选地，蛋白质是人生长激素。

2. 发明申请

WO2004062561A3 PHARMACEUTICAL COMPOSITIONS COMPRISING FENTANYL FOR INTRANASAL DELIVERY 审中-公开
标题翻译：包含FENTANYL用于手工输送的药物组合物
公开(公告)号：WO2004062561A3
公开(公告)日：2004-10-07
申请号：PCT/GB2004000057
申请日：2004-01-12
申请人： WEST PHARM SERV DRUG RES LTD , CASTILE JONATHAN DAVID , WATTS PETER JAMES , LAFFERTY WILLIAM COLUMBUS IAN , SMITH ALAN
发明人： CASTILE JONATHAN DAVID , WATTS PETER JAMES , LAFFERTY WILLIAM COLUMBUS IAN , SMITH ALAN
IPC分类号： A61K9/00 , A61K31/4468 , A61P25/04
CPC分类号： A61K31/4468 , A61K9/0043 , A61K47/26 , A61K47/36 , A61M11/00 , A61M15/08
摘要： This invention provides a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal, which comprises an aqueous solution of (i) fentanyl or a pharmaceutically acceptable salt thereof and (ii) a pharmaceutically acceptable additive selected from (a) a pectin and (b) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of- that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose.
摘要翻译：本发明提供了一种用于鼻内递送芬太尼或其药学上可接受的盐的动物的组合物，其包含（i）芬太尼或其药学上可接受的盐的水溶液和（ii）选自（a）的药学上可接受的添加剂，果胶和（b）泊洛沙姆和壳聚糖或其盐或衍生物; 条件是当组合物包含果胶时，其基本上不含二价金属离子; 并且与相同剂量的鼻内给药的芬太尼的简单水溶液相比，提供芬太尼（C max）的峰值血浆浓度为10至80％，其使用芬太尼简单的水溶液在鼻内施用相同的芬太尼剂量。

3. 发明申请

WO03090722A2 MICROPARTICLE PHARMACEUTICAL COMPOSITIONS FOR INTRATUMORAL DELIVERY 审中-公开
标题翻译：用于腹腔内输送的微量药物组合物（MICROPARTICLE PHARMACEUTICAL COMPOSITIONS FOR INTRALUMORAL DELIVERY）
公开(公告)号：WO03090722A2
公开(公告)日：2003-11-06
申请号：PCT/US0313018
申请日：2003-04-24
申请人： TEVA PHARMA , WEST PHARM SERV DRUG RES LTD , TEVA PHARMA , WEST PHARM SERV INC , LERNER E ITZHAK , FLASHNER-BARAK MOSHE , TZAFRIRI ABRAHAM , PARNESS HANNA , SMITH ALAN , HINCHCLIFFE MICHAEL
发明人： LERNER E ITZHAK , FLASHNER-BARAK MOSHE , TZAFRIRI ABRAHAM , PARNESS HANNA , SMITH ALAN , HINCHCLIFFE MICHAEL
IPC分类号： A61K9/14 , A61K9/00 , A61K9/16 , A61K31/337 , A61K47/30 , A61K47/32 , A61K47/36 , A61K47/38 , A61P35/00
CPC分类号： A61K9/1635 , A61K9/0019 , A61K31/337 , A61K47/32
摘要： Provided are microparticles including paclitaxel, methods for making them, and pharmaceutical compositions containing them. Also provided are methods of treating tumors including the step of intratumorally injecting the paclitaxel-containing microspheres of the present invention.
摘要翻译：提供包括紫杉醇的微粒，其制备方法和含有它们的药物组合物。还提供了治疗肿瘤的方法，包括肿瘤内注射本发明的含有紫杉醇的微球的步骤。

4. 发明申请

WO2005060945A3 INTRANASAL COMPOSITIONS COMPRISING ZOLPIDEM 审中-公开
标题翻译：包含ZOLPIDEM的INTRANASAL组合物
公开(公告)号：WO2005060945A3
公开(公告)日：2005-12-22
申请号：PCT/GB2004005446
申请日：2004-12-23
申请人： ARCHIMEDES DEV LTD , CASTILE JONATHAN DAVID , CHENG YU-HUI , JENKINS PAUL GEORGE , SMITH ALAN , WATTS PETER JAMES
发明人： CASTILE JONATHAN DAVID , CHENG YU-HUI , JENKINS PAUL GEORGE , SMITH ALAN , WATTS PETER JAMES
IPC分类号： A61K9/00 , A61K9/16 , A61K31/4184 , A61K47/36 , A61K47/40 , A61K47/48
CPC分类号： B82Y5/00 , A61K9/0043 , A61K9/1623 , A61K9/1652 , A61K31/4184 , A61K47/36 , A61K47/40 , A61K47/6951 , Y10S514/923
摘要： The present invention provides compositions for the intranasal administration of zolpidem or a pharmaceutically acceptable salt thereof. Preferred compositions of the invention are in the form of aqueous solutions. Optionally the compositions of the invention comprise a cyclodextrin and/or chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention insomnia or the treatment of neurological disorders such as those arising from brain trauma, stroke and spinocerebellar ataxia or in the treatment of Parkinson's disease.
摘要翻译：本发明提供了用于鼻内施用唑吡旦或其药学上可接受的盐的组合物。本发明的优选组合物是水溶液的形式。任选地，本发明的组合物包含环糊精和/或壳聚糖，其盐或衍生物或壳聚糖衍生物的盐。该组合物可用于治疗或预防失眠或治疗诸如由脑创伤，中风和脊髓小脑共济失调引起的神经障碍或治疗帕金森病。

5. 发明申请

WO2009027697A3 NON-AQUEOUS PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：非水性药物组合物
公开(公告)号：WO2009027697A3
公开(公告)日：2010-04-01
申请号：PCT/GB2008002940
申请日：2008-08-29
申请人： ARCHIMEDES DEV LTD , WATTS PETER JAMES , CHENG YU-HUI , SMITH ALAN , CASTILE JONATHAN
发明人： WATTS PETER JAMES , CHENG YU-HUI , SMITH ALAN , CASTILE JONATHAN
IPC分类号： A61K9/00 , A61K9/08 , A61K31/55 , A61K31/5517 , A61K47/10 , A61K47/14 , A61K47/22
CPC分类号： A61K9/0043 , A61K9/08 , A61K31/55 , A61K31/5517 , A61K47/10 , A61K47/14 , A61K47/22
摘要： The present invention provides a composition for intranasal delivery of a drug comprising: (i) the drug; and (ii) a non-aqueous vehicle comprising (a) propylene glycol and at least one additional solvent selected from N-methylpyrrolidone, propylene carbonate, dimethyl sulfoxide and at least one propylene glycol fatty acid ester; (b) from about 40 to 100 % by volume of N- methylpyrrolidone; or (c) from about 40 to 100% by volume of dimethyl sulfoxide (DMSO).
摘要翻译：本发明提供了用于鼻内递送药物的组合物，其包含：（i）药物; 和（ii）非水性载体，其包含（a）丙二醇和至少一种另外的选自N-甲基吡咯烷酮，碳酸亚丙酯，二甲基亚砜和至少一种丙二醇脂肪酸酯的溶剂; （b）约40-100％（体积）N-甲基吡咯烷酮; 或（c）约40〜100体积％的二甲基亚砜（DMSO）。

6. 发明申请

WO0129046A3 A SALT OF MORPHINE 审中-公开
标题翻译：一种盐的盐
公开(公告)号：WO0129046A3
公开(公告)日：2001-11-01
申请号：PCT/GB0004003
申请日：2000-10-19
申请人： WEST PHARM SERV DRUG RES LTD
发明人： ILLUM LISBETH , WATTS PETER , SMITH ALAN , LAFFERTY IAN
IPC分类号： A61K9/06 , A61K9/08 , A61K9/10 , A61K9/14 , A61K9/52 , A61K31/485 , A61K47/36 , A61P25/04 , C07D489/04
CPC分类号： C07D489/04
摘要： The methane sulphonate salt of morphine and compositions thereof are described. Also described is a composition adapted for nasal delivery comprising a methane sulphonate salt of an opioid analgesic.
摘要翻译：描述了吗啡的甲磺酸盐及其组合物。还描述了适用于鼻输送的组合物，其包含阿片类镇痛剂的甲磺酸盐。

7. 发明申请

WO2007068948A2 PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：药物组合物
公开(公告)号：WO2007068948A2
公开(公告)日：2007-06-21
申请号：PCT/GB2006004710
申请日：2006-12-15
申请人： ARCHIMEDES DEV LTD , SMITH ALAN , DYER ANN MARGARET
发明人： SMITH ALAN , DYER ANN MARGARET
IPC分类号： A61K31/195 , A61K9/20 , A61K9/48 , A61P5/14 , A61P9/04
CPC分类号： A61K9/2009 , A61K9/1611 , A61K9/2054 , A61K9/2095 , A61K9/2866 , A61K31/195
摘要： There is provided sustained release pharmaceutical compositions comprising a drug; microcrystalline cellulose; a diluent (such as starch); a glidant (such as talc); and one or more of ethylcellulose, stearic acid and a salt of stearic acid. Preferred drugs include those that exhibit a low degree of solubility combined with a high potency, particularly thyroid hormones, such as liothyronine.
摘要翻译：提供包含药物的持续释放药物组合物; 微晶纤维素; 稀释剂（如淀粉）; 助流剂（如滑石粉）; 和一种或多种乙基纤维素，硬脂酸和硬脂酸盐。优选的药物包括与高效力结合的低溶解度的药物，特别是甲状腺激素，如氨基罗丹宁。

8. 发明申请

WO02095358A3 SYSTEM AND METHOD FOR MONITORING OR TREATING A HEALTH CONDITION 审中-公开
标题翻译：用于监测或治疗健康状况的系统和方法
公开(公告)号：WO02095358A3
公开(公告)日：2003-03-06
申请号：PCT/US0216130
申请日：2002-05-20
申请人： SPECTRX INC , FAUPEL MARK , MARCUS RAULEE , SMITH ALAN , YANG DIFEI
发明人： FAUPEL MARK , MARCUS RAULEE , SMITH ALAN , YANG DIFEI
IPC分类号： A61B5/00 , A61B5/103
CPC分类号： A61B5/145 , A61B5/14514 , A61B5/14532 , A61B5/14546 , A61B5/441 , A61B5/4839
摘要： The present invention relates to a system and method for monitoring or treating a health condition. The method can include accessing a biological fluid, evaluating an analyte in the fluid, presenting a measurement parameter based on the evaluation, and/or administering a treatment based on the evaluation. The measurement parameter can prompt administering a treatment. The system can include a fluid handling device, a display and/or alert device, and/or an administration device. This abstract is provided for searching purposes only and is not meant for construing the claims.
摘要翻译：本发明涉及用于监测或治疗健康状况的系统和方法。该方法可以包括进入生物流体，评估流体中的分析物，基于评估呈现测量参数，和/或基于评估进行治疗。测量参数可以促进治疗。该系统可以包括流体处理装置，显示器和/或警报装置，和/或管理装置。本摘要仅用于搜索目的，而不是用于解释权利要求。

9. 发明申请

WO0135820A9 TISSUE INTERFACE DEVICE 审中-公开
标题翻译：组装界面装置
公开(公告)号：WO0135820A9
公开(公告)日：2002-05-16
申请号：PCT/US0031765
申请日：2000-11-17
申请人： SPECTRX INC , ALTEA TECH INC , FAUPEL MARK L , KUMAR KRISHNA , FARQUHAR DAVID , VREEKE MARK , SMITH ALAN , HATCH MICHAEL , WOODS TERESA
发明人： FAUPEL MARK L , KUMAR KRISHNA , FARQUHAR DAVID , VREEKE MARK , SMITH ALAN , HATCH MICHAEL , WOODS TERESA
IPC分类号： G01N33/487 , A61B5/00 , G01N33/48
CPC分类号： A61B5/1486
摘要： A tissue interface device (10) suitable for positioning on or about one or more artificial openings in a biological membrane of an organism and for coupling to a monitor and control unit and a vacuum source. The tissue interface device (10) comprises a housing (100), a sensor channel (130), and a sensor (150). The housing (100) defines an orifice (120), the orifice (120) having an open inlet port (122) on the bottom end (102) of the housing (100) and a distal end (124) that is in fluid communication with the sensor channel (130). The orifice (120) is in fluid communication with fluid that flows from the artificial opening formed in the biological membranes. The sensor channel (130) is for coupling to, and fluid communication therewith, the vacuum source. The sensor (150) is positioned in the sensor channel (130) in a flow path of the fluid for sensing a characteristic of the fluid as it flows out from the artificial opening. The sensor generates a sensor signal representative thereof.
摘要翻译：适于定位在生物体的生物膜中的一个或多个人造开口上或周围的组织界面装置（10），并用于耦合到监测和控制单元和真空源。组织接口装置（10）包括壳体（100），传感器通道（130）和传感器（150）。壳体（100）限定孔口（120），孔口（120）在壳体（100）的底端（102）上具有开放的入口端口（122）和远端（124），该远端端部与传感器通道（130）连接。孔口（120）与从生物膜中形成的人造开口流动的流体流体连通。传感器通道（130）用于耦合到真空源并与之流体连通。传感器（150）在流体的流动路径中位于传感器通道（130）中，用于感测流体从人造开口流出时的特性。传感器产生代表其的传感器信号。

10. 发明申请

WO2006138658A2 PERMEANT DELIVERY SYSTEM AND METHODS FOR USE THEREOF 审中-公开
标题翻译：渗透剂输送系统及其使用方法
公开(公告)号：WO2006138658A2
公开(公告)日：2006-12-28
申请号：PCT/US2006023640
申请日：2006-06-19
申请人： ALTEA THERAPEUTICS CORP , EPPSTEIN JONATHAN , ENSCORE DAVID , TAGLIAFERRI FRANK , TOLIA GAURAV , CHANG SHULUN , SMITH ALAN , PATEL YOGI , MCRAE STUART
发明人： EPPSTEIN JONATHAN , ENSCORE DAVID , TAGLIAFERRI FRANK , TOLIA GAURAV , CHANG SHULUN , SMITH ALAN , PATEL YOGI , MCRAE STUART
IPC分类号： A61K9/24
CPC分类号： A61K9/7053 , A61K9/0009
摘要： Disclosed is a device for causing the transdermal flux of a permeant into a subject via at least one formed pathway through a skin layer of the subject. The device comprises a delivery reservoir comprising: i) a non-biodegradable matrix having a bottom surface and defining a plurality of conduits therein the matrix, at least a portion of the plurality of conduits being in communication with the bottom surface; and ii) an undissolved hydrophilic permeant disposed therein at least a portion of the plurality of conduits of the matrix, wherein the hydrophilic permeant can come in contact with subcutaneous fluid from the subject when the bottom surface of the matrix is positioned in fluid communication with the at least one formed pathway. Also disclosed are systems and methods for causing the transdermal flux of a permeant into a subject via at least one formed pathway through a skin layer of the subject.
摘要翻译：公开了一种用于通过穿过受试者的皮肤层的至少一个形成的途径使得渗透物经皮通流入受试者的装置。所述装置包括输送储存器，其包括：i）具有底表面并且在其中限定所述基质中的多个导管的不可生物降解的基质，所述多个导管的至少一部分与所述底表面连通; 和ii）在所述基质的所述多个导管的至少一部分中设置未溶解的亲水性渗透物，其中当所述基质的底表面位于与所述基质的流体连通时，所述亲水性透过物可与来自所述受试者的皮下流体接触至少一个形成的途径。还公开了一种系统和方法，用于通过穿过受试者的皮肤层的至少一个形成的途径使渗透物的经皮通流进入受试者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式